19 results about "Plasma derived" patented technology

The invention relates to the technical field of antibiosis, in particular to an AIE type cationic conjugated polymer, a preparation method, plasma activated hydrogel and application. The AIE type cationic conjugated polymer has the following structural formula. By combining an FADM photosensitizer with remarkable aggregation-induced emission characteristics and efficient ROS generation capability with a cold atmospheric pressure plasma technology, a hydrogel material with photodynamic and plasma-derived reactive oxygen species synergistic antibacterial functions is constructed, and the problems that RONS in PAW is extremely short in half-life period, low in viscosity and poor in antibacterial effect are solved. The active ingredients are difficult to effectively enrich and maintain at the infected part.

The present invention relates to a method and system for extracting proteins from precipitates, particularly recombinant and / or plasma derived proteins including immunoglobulins (Ig) such as immunoglobulin G (IgG).

A method of treating neurodegenerative diseases using hUCB plasma is presented herein. hUCB plasma attenuated the hyperactive response (Group III) and potentiated the normal response in Group I ALS patients, but did not alter that of the non-responders to PHA (Group II). The elevated activity of caspase 3 / 7 observed in the MNCs from ALS patients was significantly reduced by hUCB plasma treatment. The ability of hUCB plasma to modulate the mitogen cell response and reduce caspase activity suggest that the use of hUCB plasma alone, or with stem cells, may prove useful as a therapeutic in ALS patients. hUCB plasma was shown to increase therapeutic efficacy of MNCs as well as decrease apoptosis of MNCs. The cytokine profile of hUCB plasma supports its usefulness as a sole therapeutic as well as an additive to MNCs.

The invention relates to the technical field of biology, in particular to a method and a reagent for directly detecting gene methylation based on a Cas12a system and application of the method and the reagent. According to the method for directly detecting the gene methylation of the gene in the Cas12a system, disclosed by the invention, a Cas12a protein and specific Multiplex-gRNAs of a target gene are combined in a CRISPR-Cas12a buffer system to form a compound, the target gene is specifically recognized, the trans-cleavage activity of the Cas12a protein is activated, a fluorescence-labeled reporter probe is cleaved to generate a fluorescence signal, and the methylation of the gene is directly detected in the CRISPR-Cas12a buffer system. Qualitative / quantitative analysis of target gene methylation is carried out by detecting the intensity of a fluorescence signal generated by a Cas12a protein trans-cleavage fluorescence labeled reporter probe. The method has the advantages that hydrosulfite pretreatment and amplification are not needed, and the complex process and sensitivity limitation of a traditional methylation detection technology are remarkably broken through. The methylation state of the target DNA can be quickly distinguished, and the result can be read within 30 minutes in the whole detection process. Compared with the prior art, the method disclosed by the invention has the characteristics of simplicity and convenience in operation, no amplification pollution risk, low requirement on sample concentration and the like, and is particularly suitable for rapid detection of methylation sites in cfDNA samples from clinical plasma and auxiliary diagnosis of cancers.

The application discloses application of plasma-derived exosomes in preparation of drugs for improving or treating oral diseases. The plasma-derived exosomes have good biological effects of inhibiting inflammation, promoting angiogenesis and accelerating lesion healing, can accelerate healing of mucosal injury by inhibiting release of inflammatory factors and chemotactic factors, and thus reduce progress of inflammation. In addition, the plasma-derived exosomes can promote proliferation of human oral epithelial cells and healing of scratches, and have good effects in improving oral diseases.

The present inventors examined the procoagulant activity of a multispecific antigen-binding molecule that functionally substitutes for FVIII using blood and plasma derived from FIX disorder patients. The result showed that multispecific antigen-binding molecules that functionally substitute for FVIII can be used not only as methods for preventing and / or treating bleeding in hemophilia A, acquired hemophilia A, von Willebrand disease, and hemophilia C, which are caused by FVIII dysfunction, but also as methods for preventing and / or treating bleeding in FIX disorders, because of their procoagulant activity. Furthermore, the effect of a FIX formulation could be enhanced by using it in combination with a multispecific antigen-binding molecule that functionally substitutes for FVIII, and it was shown that the combined use is promising as a combination therapy that shows stable hemostatic effects.

A plasma testing system includes a plasma collection bottle, having a body and an opening. The blood plasma bottle is configured to contain plasma, and a cartridge connectable to the opening of the bottle. The cartridge is configured to seal the opening of the bottle and includes plasma testing circuitry to test the plasma. The system further has a testing platform including at least one receptacle configured to receive the plasma collection bottle and the cartridge. The at least one receptacle has receiving circuitry in communication with the testing circuitry to receive a test result of the plasma test of the plasma.

The present invention relates to a method and system for extracting proteins, in particular recombinant and / or plasma-derived proteins, including immunoglobulins (Ig), such as immunoglobulin G (IgG), from precipitate.

Disclosed are methods, kits, systems, and platforms for testing, diagnosing, and treating subjects suffering from symptoms of or diagnosed with an esophageal gastric acid-related disease or condition.

Provided herein are recombinant AAT proteins having high fucosylation levels and enhanced immunomodulatory biological activity as compared to a plasma derived AAT. Further provided are compositions including the same and methods for preparation thereof.

The present disclosure provides methods for improving diagnostic applications by using genome-wide patterns of plasma-derived fragmented cell-free DNA (cfDNA) derived by low-coverage whole genome sequencing. In particular, the present invention provides a new and effective method for subtyping non-small cell lung cancer in a subject as low-neuroendocrine non-small cell lung cancer or high-neuroendocrine non-small cell lung cancer.

The invention provides application of plasma-derived EVs after RIPC in preparation of a medicine for preventing and / or treating kidney injury, and belongs to the technical field of biological medicine. The RIPC plasma-derived EVs provided by the invention can be used for preparing medicines for preventing and / or treating kidney injury caused by unilateral ureteral obstruction combined with pelvic lipopolysaccharide (LPS) injection. In-vivo and in-vitro experiments prove that compared with normal plasma-derived EVs, the plasma-derived EVs after RIPC shows a remarkable and better protection effect on U-L model kidney injury and LPS-induced HK-2 cell injury. Therefore, by taking the EVs from the plasma after RIPC as the active ingredient, the application has a wide prospect in developing a novel treatment medicine for treating the obstruction complicated with the inflammatory renal injury.

The present invention relates to the fields of biotechnology and molecular detection technology, and in particular to a circRNA for the diagnosis and / or treatment of gastric cancer, its application, detection primer pairs, and diagnostic kit. Based on circRNA chip sequencing of plasma-derived exosomes (exosomes), the present invention screened and found that hsa_circ_0012172 showed significant differences in plasma exosomes from gastric cancer patients and healthy subjects, suggesting that it could be used as a potential non-invasive biomarker for gastric cancer. Furthermore, through functional experiments, the present invention also found that hsa_circ_0012172 has a significant anti-cancer effect. Overexpression of hsa_circ_0012172 can significantly inhibit the proliferation, migration, and invasion of gastric cancer cells, suggesting that it could become a potential target for gastric cancer treatment, providing new ideas for gastric cancer treatment.

The invention discloses an immunoaffinity separation method of hepatocyte-derived small extracellular vesicles in plasma and application of the immunoaffinity separation method, and relates to the technical field of biology. The separation method comprises the following steps: constructing a transgenic animal of which the hepatocyte specifically expresses the methionine-tRNA synthetase L274G mutant; the L-azido-n-leucine is administered into the transgenic animal, so that the transgenic animal expresses L-azido-n-leucine labeled protein; collecting and identifying L-azido-n-leucine labeled proteins in plasma-derived small extracellular vesicles, liver-derived small extracellular vesicles and liver tissues of the transgenic animal, carrying out cross analysis, and screening overlapped and highly expressed biomarkers; providing an antibody of the biomarker, and separating to obtain the hepatocyte-derived small extracellular vesicles in plasma through antigen-antibody specific binding. The effect of separating the hepatocyte-derived small extracellular vesicles by using the screened biomarker is remarkable, and a new thought and method are provided for disease diagnosis.

The application discloses application of exosome miRNA markers in evaluation of curative effect of immunotherapy combined with chemotherapy on small cell lung cancer patients. The exosome miRNA markers are a combination of miR-338-5p, miR-345-5p, miR-150-5p, miR-7706 and miR-328-3p. It is found for the first time that a combination of plasma exosome miRNA and TNM stage can be used as a marker to effectively predict a population benefiting from an immunotherapy combined with chemotherapy treatment scheme. Due to the unique structure of the exosome and the advantages of liquid biopsy technology, the exosome miR-338-5p, miR-345-5p, miR-150-5p, miR-7706, miR-328-3p and TNM stage combination of the application has high sensitivity and convenience as a population screening for benefiting from an immunotherapy combined with chemotherapy combined treatment scheme.

The present application relates to methods of treating infectious diseases with compositions containing plasma-derived immunoglobulin M (IgM). The compositions and methods of the invention prevent, inhibit, or reduce the toxic effects of proteins and toxins secreted by microorganisms. A method for neutralizing a microbial protein product in a subject includes administering to the subject a composition comprising plasma-derived IgM and, optionally, one or more excipients in the form of a pharmaceutical carrier, wherein the composition is administered in an amount effective to neutralize the microbial protein product.

The invention relates to the technical field of biomedical materials, and discloses inulin gel, exosome inulin gel and a preparation method and application thereof.The inulin gel is prepared from inulin and a solvent, the inulin is prepared into the gel through a heating-cooling method, the inulin is dissolved through heating, the gel is formed through the crowding effect of the inulin, and the exosome inulin gel is prepared from the solvent. The exosome inulin gel relates to a solvent, inulin and an exosome, and the exosome can be a milk exosome, a plant exosome, a mesenchymal stem cell exosome, a plasma source exosome or a macrophage source exosome. According to the exosome inulin gel as well as the preparation method and the application thereof, the heating-cooling preparation method of the inulin gel and the exosome-inulin gel is simple and convenient to operate and easy to implement, meanwhile, the preparation time is short, the process stability is good, the gel uniformity is good, and meanwhile, a mouse burn wound model is used for carrying out an in-vivo experiment, so that the in-vivo experiment result is good. It is verified that the hydrogel can promote healing of wounds such as burns and scalds.

The present application relates to the field of antibacterial technology, in particular to an AIE type cationic conjugated polymer and a preparation method, plasma activated hydrogel and application. The AIE type cationic conjugated polymer has the following structural formula. The present application combines the FADM photosensitizer with significant aggregation-induced emission characteristics and high ROS generation capacity with cold atmospheric pressure plasma technology, constructs a hydrogel material with synergistic antibacterial function of photodynamic and plasma derived reactive oxygen nitrogen species, and solves the problem that the half-life of RONS in PAW is extremely short, and the low viscosity leads to the difficulty of effective enrichment and maintenance of active ingredients in the infection site.

The invention relates to the technical field of molecular biology, in particular to application of miRNA in preparation of a kit for detecting hepatic fibrosis and the kit, and the miRNA comprises one or more of miR-139-5p, miR-126a-3p, miR-10a-5p and miR-381-3p. Through verification of significant disorder of miR-139-5p and miR-10a-5p in plasma of a patient with hepatic fibrosis and significant disorder of miR-126a-3p, miR-381-3p and miR-10a-5p in plasma-derived EV of a patient with decompensated hepatic fibrosis, the miR-139-5p-miR-139-5p-miR-139-5p-miR-139-5p-miR-139-5p-miR-139-5p-miR-139-5p-miR-139-5p-miR-139-5p- In clinical detection, the method comprises the following steps: collecting the RNA of the plasma of a patient, separating and purifying the exosomes in the plasma of the patient through an ultracentrifugation method, extracting the RNA of the exosomes, and detecting whether miRNA in the exosomes from the plasma is obviously imbalanced or not by utilizing a qRT-PCR (quantitative reverse transcription-polymerase chain reaction) technology, so as to judge whether the patient has the tendency of hepatic fibrosis or not.